Oxford BioDynamics Issues Shares to Preserve Cash

Oxford BioDynamics ( (GB:OBD) ) has shared an update.

Oxford BioDynamics announced the issuance of 2,742,657 new ordinary shares as part of its strategy to conserve cash by compensating its directors and senior staff with shares in lieu of salary. This move is aligned with the company’s ongoing financial strategy and reflects its commitment to maintaining cash resources while rewarding key personnel. The new shares will be traded on AIM from 31 December 2024, adjusting the company’s total issued share capital and voting rights to 319,319,226 shares, impacting shareholder calculations under transparency regulations.

More about Oxford BioDynamics

Oxford BioDynamics Plc (AIM: OBD) is a biotechnology company that develops and commercializes precision clinical diagnostic tests using its EpiSwitch® 3D genomic biomarker platform. The company focuses on personalized healthcare with products like the EpiSwitch® PSE for prostate cancer screening and the EpiSwitch® CiRT for predicting responses to immuno-oncology treatments. Headquartered in Oxford, UK, it operates globally with facilities in the USA and Malaysia, and is listed on the London Stock Exchange’s AIM.

YTD Price Performance: -95.81%

Average Trading Volume: 4,605,487

Technical Sentiment Consensus Rating: Buy

Current Market Cap: £3.71M

For detailed information about OBD stock, go to TipRanks’ Stock Analysis page.